Drug Profile
Doxorubicin liposomal - 2-BBB Medicines
Alternative Names: 2B3-101; 2X-111; Doxorubicin glutathione-pegylated liposome therapeutic - 2-BBB MedicinesLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator to-BBB technologies
- Developer 2-BBB Medicines
- Class Anthracyclines; Antineoplastics; Antivirals; Cytostatic antibiotics; Doxorubicins; Hepatoprotectants; Small molecules
- Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Brain metastases; Glioma
Most Recent Events
- 26 Oct 2020 Allarity Therapeutics receives patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US
- 07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics
- 29 Jun 2020 Oncology Venture A/S out-licenses Doxorubicin liposomal to Smerud Medical Research International for clinical and commercial development